Pyxis Oncology develops a portfolio of clinical ADC and monoclonal antibody immunotherapy candidates for patients with cancer, led by the ADC MICVO aimed at the tumor microenvironment and combining antibody discovery with conjugation technology. It operates both an antibody discovery platform and an antibody conjugation technology platform: the Pfizer-developed FACT platform builds next-generation ADCs with greater stability, potency and tumor penetration, while the APXiMAB platform produces antibodies that serve as ADC backbones and as immunotherapy candidates.
Pyxis Oncology's lead candidate targets an extracellular-matrix protein that tumors overexpress and normal adult tissue largely lacks. The company positions ADCs against traditional cytotoxic cancer treatments on targeted delivery, better efficacy and lower toxicity, pairing an antibody with a drug to deliver it directly to cancer cells. Its biologics target tumor cells and address immune suppression.
